Results 11 to 20 of about 3,859 (214)
Dose-Related α-Difluoromethylornithine Ototoxicity [PDF]
American Journal of Clinical Oncology, 1991 We assessed the ototoxicity associated with oral alpha-difluoromethylornithine (DFMO) administration in 58 patients with metastatic malignant melanoma. One hundred seventy-nine sequential audiograms obtained from patients treated with DFMO alone (16 patients) or in combination with alpha 2b-interferon (42 patients) were evaluated.
Croghan, Marilyn K +2 more
openaire +6 more sources
Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome
EMBO Molecular Medicine, 2023 Snyder–Robinson syndrome (SRS) results from mutations in spermine synthase (SMS), which converts the polyamine spermidine into spermine. Affecting primarily males, common manifestations of SRS include intellectual disability, osteoporosis, hypotonia, and
Tracy Murray Stewart +8 more
doaj +2 more sources
Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression
npj Precision Oncology, 2017 Esophageal cancer: African sleeping sickness drug shows activity against tumors Blocking an enzyme involved in the cellular synthesis of essential compounds called polyamines could help treat esophageal cancer.
Wei He +8 more
doaj +2 more sources
Medical Sciences, 2022 Polyamine biosynthesis is frequently dysregulated in cancers, and enhanced flux increases intracellular polyamines necessary for promoting cell growth, proliferation, and function.
Alexander Chin +3 more
doaj +1 more source
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
Cureus, 2023 Neuroblastoma is a type of cancer that affects the sympathetic nervous system and is the most common extracranial solid tumor in children. Difluoromethylornithine (DFMO) is a drug that has shown promise as a treatment option for high-risk neuroblastoma.
Tangella, Adarsh Vardhan +3 more
openaire +2 more sources
Difluoromethylornithine: The Proof Is in the Polyamines [PDF]
Cancer Prevention Research, 2012 AbstractIn this issue (beginning on page 1368), Kreul and colleagues report a retrospective review of long-term efficacy and toxicity for subjects participating in a phase III study of difluoromethylornithine (DFMO) for prevention of nonmelanoma skin cancer (NMSC).
Joanne M, Jeter, David S, Alberts
openaire +2 more sources
Difluoromethylornithine (DFMO) and AMXT 1501 inhibit capsule biosynthesis in pneumococci
Scientific Reports, 2022 Polyamines are small cationic molecules that have been linked to various cellular processes including replication, translation, stress response and recently, capsule regulation in Streptococcus pneumoniae (Spn, pneumococcus).
Moses B. Ayoola +7 more
doaj +1 more source
Characterization of the Ototoxicity of Difluoromethylornithine and Its Enantiomers [PDF]
Toxicological Sciences, 2000 Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the essential enzyme in mammalian polyamine biosynthesis (Pasic et al., 1997, Arch. Otolaryngol. Head Neck Surg. 123[12], 1281-1286). This cancer chemotherapeutic agent has significant ototoxic potential. Because the DFMO enantiomers differ in their ability to
M L, McWilliams, G D, Chen, L D, Fechter
openaire +2 more sources
Convenient Synthesis of α-Difluoromethylornithine [PDF]
Bioscience, Biotechnology, and Biochemistry, 1993 (1993). Convenient Synthesis of α-Difluoromethylornithine. Bioscience, Biotechnology, and Biochemistry: Vol. 57, No. 6, pp. 1024-1025.
Masahiko Seki +2 more
openaire +1 more source
DMSO-tolerant ornithine decarboxylase (ODC) tandem assay optimised for high-throughput screening
Journal of Enzyme Inhibition and Medicinal Chemistry, 2023 Ornithine decarboxylase (ODC), the first rate-limiting enzyme in polyamine synthesis, has emerged as a therapeutic target for cancer and Alzheimer’s disease (AD).
Mingu Gordon Park +2 more
doaj +1 more source